Biological therapy for heumatoid arthritis: Where are we now?

British Journal of Hospital Medicine

Volumn 73, Issue 1, 2012, Pages 12-18

  Horton, Sarah C ^a   Emery, Paul ^b  

^a Specialty Registrar in Rheumatology   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

DRUG ANTAGONISM; HUMAN; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; METHOTREXATE; MOLECULAR TARGETED THERAPY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855998079     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2012.73.1.12     Document Type: Conference Paper

References (32)

1. Bathon JM, Martin RW, Fleischmann RM et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343(22): 1586-93 (Pubitemid 32162981)
2. Bejarano V, Conaghan PG, Quinn MA, Saleem B, Emery P (2010) Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology 49(10): 1971-4
3. Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1): 26-37 (Pubitemid 43122183)
4. Conaghan PG, Quinn MA, O'Connor P, Wakefield RJ, Karim Z, Emery P (2002) Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission? Arthritis Rheum 46(7): 1971-2
5. Dixon WG, Symmons DPM, Lunt M, Watson KD, Hyrich KL, Silman AJ (2007) Serious infection following anti-tumor necrosis factor > therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum 56(9): 2896-904 (Pubitemid 47502735)
6. Dixon WG, Hyrich KL, Watson KD et al (2010a) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69(3): 522-8
7. Dixon WG, Watson KD, Lunt M et al (2010b) Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for Rheumatology Biologics Register. Arthritis Care Res 62(6): 755-63
8. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54(5): 1390-400
9. Emery P, Breedveld FC, Hall S et al (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372(9636): 375-82
10. Emery P, Fleischmann RM, Moreland LW et al (2009) Golimumab, a human anti-tumor necrosis factor ?lt;?monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebocontrolled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60(8): 2272-83
11. Emery P, Kvein TK, Combe B et al (2010) Very early (<4 months) treatment with combination etanercept and methotrexate produces significantly better remission rates: results from the COMET study. Ann Rheum Dis 69(Suppl 3): 57
12. Genovese MC, Breedveld FC, Emery P et al (2010) An assessment of the serious infection rate in rituximab-treated rheumatoid arthritis (RA) patients who subsequently received other biologic therapies: a follow-up from rituximab clinical trials. Rheumatology 49(Suppl 1): i3-i5
13. Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Allaart CF et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 52(11): 3381-90 (Pubitemid 41612204)
14. Hyrich KL, Watson KD, Silman AJ, Symmons DP (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 45(12): 1558-65 (Pubitemid 44817065)
15. Keystone E, Van Der Heijde D, Mason D et al (2008) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fiftytwo- week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58(11): 3319-29
16. Keystone EC, Genovese MC, Klareskog L et al (2009) Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis 68(6): 789-96
17. Kremer JM, Genant HK, Moreland LW et al (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. Ann Intern Med 144(12): 865-76 (Pubitemid 46768126)
18. Maini R, St Clair EW, Breedveld F et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354(9194): 1932-9
19. Quinn MA, Conaghan PG, O'Connor PJ et al (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52(1): 27-35 (Pubitemid 40129229)
20. Saleem B, Keen H, Goeb V et al (2010) Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 69(9): 1636-42
21. Smolen JS, Beaulieu A, Rubbert-Roth A et al (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebocontrolled, randomised trial. Lancet 371(9617): 987-97 (Pubitemid 351392039)
22. Smolen JS, Aletaha D, Bijlsma JW et al (2010a) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4): 631-7
23. Smolen JS, Landewe R, Breedveld FC et al (2010b) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6): 964-75
24. Soubrier M, Puechal X, Sibilia J et al (2009) Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology 48(11): 1429-34
25. St Clair EW, Van Der Heijde D, Smolen JS et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11): 3432-43 (Pubitemid 39488667)
26. Tak PP, Rigby WF, Rubbert-Roth A et al (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70(1): 39-46
27. van Vollenhoven RF, Ernestam S, Geborek P et al (2009) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomized trial. Lancet 374(9688): 459-66
28. van Vollenhoven RF, Emery P, Bingham CO et al (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37(3): 558-67
29. Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor > monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 48(1): 35-45 (Pubitemid 36091645)
30. Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340(4): 253-9 (Pubitemid 29063266)
31. Westhovens R, Robles M, Ximenes AC et al (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68(12): 1870-7
32. Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum 56(9): 2886-95 (Pubitemid 47502734)